IP Library Granted Patent US 8,084,441
Granted Patent B2
US 8,084,441 · App. 12/804,478 · Granted Dec 27, 2011

Cystitis treatment with high dose chondroitin sulfate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,441
App. No.
12/804,478
Granted
Dec 27, 2011
Kind
B2
Abstract

Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis.

Claims (17)

1. A method of treating cystitis in a subject in need thereof, the method comprising:

treating the subject with a pharmaceutical composition comprising:

a unit dose of chondroitin sulfate in an amount of at least 350 mg, and

an aqueous vehicle in a volume of from 10 mL to 100 mL,

wherein the pharmaceutical composition is adapted for instillation to the bladder of the subject, so as to treat the cystitis in the subject.

2. The method according to claim 1 , wherein the chondroitin sulfate is present in an amount of 400 mg.

3. The method according to claim 1 , wherein the aqueous vehicle is present in an amount of 20 mL.

4. The method according to claim 1 , wherein the aqueous vehicle is phosphate-buffered saline.

5. The method according to claim 1 , wherein the cystitis is interstitial cystitis.

6. The method according to claim 1 , wherein treating cystitis with the pharmaceutical composition comprises:

providing a subject afflicted with cystitis or a related condition in which one or more cystitis symptoms are elicited in the subject afflicted upon instillation of a potassium chloride solution; and

instilling the pharmaceutical composition into the bladder or urinary tract of the subject.

7. The method according to claim 6 , wherein the instilling is performed at least once weekly for a period of at least 6 weeks.

8. The method according to claim 6 , wherein the instilling is performed at least twice weekly for a period of at least 6 weeks.

9. The method according to claim 1 , wherein the unit dose of chondroitin sulfate is at most equivalent to the solubility of chondroitin sulfate is said vehicle.

10. The method according to claim 1 , wherein the unit dose of chondroitin sulfate is less than or equal to 1200 mg.

11. The method according to claim 1 , wherein the unit dose of chondroitin sulfate is less than or equal to 800 mg.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2023
From: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS AGENT
To: NUVO PHARMACEUTICALS INC.; ARALEZ PHARMACEUTICALS CANADA INC.; NUVO PHARMACEUTICALS (IRELAND) DESIGNATED ACTIVITY COMPANY (F/K/A NUVO PHARMACEUTICALS (IRELAND) LIMITED)
Reel/Frame 062974/0236 →
SECURITY INTEREST Recorded Dec 31, 2018
From: NUVO PHARMACEUTICALS INC.; NUVO PHARMACEUTICALS (IRELAND) DESIGNATED ACTIVITY COMPANY; ARALEZ PHARMACEUTICALS CANADA INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS AGENT
Reel/Frame 047875/0410 →
CHANGE OF NAME Recorded Mar 7, 2018
From: TRIBUTE PHARMACEUTICALS CANADA INC.
To: ARALEZ PHARMACEUTICALS CANADA INC.
Reel/Frame 045518/0563 →
RELEASE OF SECURITY INTEREST Recorded Feb 5, 2016
From: SWK FUNDING LLC
To: TRIBUTE PHARMACEUTICALS CANADA, INC.
Reel/Frame 037674/0301 →
RELEASE OF SECURITY INTEREST Recorded Aug 27, 2013
From: MIDCAP FUNDING III, LLC
To: TRIBUTE PHARMACEUTICALS CANADA INC.
Reel/Frame 031093/0486 →
SECURITY AGREEMENT Recorded Aug 8, 2013
From: TRIBUTE PHARACEUTICALS CANADA LLC
To: SWK FUNDING LLC
Reel/Frame 030988/0171 →
CONFIRMATION OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 28275, FRAME 0357 Recorded Mar 20, 2013
From: TRIBUTE PHARMACEUTICALS CANADA INC.
To: MIDCAP FUNDING III, LLC, AS AGENT
Reel/Frame 030049/0126 →
MERGER Recorded Feb 21, 2013
From: STELLAR PHARMACEUTICALS INC.
To: TRIBUTE PHARMACEUTICALS CANADA INC.
Reel/Frame 029849/0376 →
SECURITY AGREEMENT Recorded May 25, 2012
From: STELLAR PHARMACEUTICALS INC.; TRIBUTE PHARMACEUTICALS CANADA LTD.; TRIBUTE PHARMA CANADA INC.
To: MIDCAP FUNDING III, LLC, AS AGENT
Reel/Frame 028275/0357 →
MERGER Recorded Jul 21, 2010
From: STELLAR INTERNATIONAL INC.
To: STELLAR PHARMACEUTICALS INC.
Reel/Frame 024819/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2010
From: RIEHL, PETER R.; HAHN, SUNGTACK S.
To: STELLAR INTERNATIONAL INC.
Reel/Frame 024950/0788 →